Several possible studies
Story checked
Real-world study compares Repatha vs. Zetia for LDL cholesterol control | STAT (opens in a new tab)
Real-world study compares Repatha vs. Zetia for LDL cholesterol control · 2026-11-05
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
Help improve NewsLink
Tell us what worked or what needs attention in this check.
The story
Real-world study compares Repatha vs. Zetia for LDL cholesterol control | STAT
Real-world study compares Repatha vs. Zetia for LDL cholesterol control · 2026-11-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 3Not checkedWhen statins aren’t enough, other cholesterol-lowering drugs come into play, and cardiologists often consider two long-approved drugs that work differently and are given by different routes.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 3Not checkedA new trial based on real-world evidence pitted injectable evolocumab (Repatha) against oral ezetimibe (Zetia).View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 3Not checkedRepatha was the winner.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref · 15 candidate papers
Achieving Risk-Specific Absolute LDL-C Threshold with PCSK9 Inhibitors: A Real-World, Single-Center Analysis.
Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne · 2026 · PubMed
Ezetimibe- A Novel Add on Treatment Strategy to Achieve Targeted LDL in Patients with Uncontrolled LDL Levels on High Dose Statin Alone
Exclusive Real World Evidence Journal · 2022 · Crossref
Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets.
Frontiers in Medicine · 2026 · PubMed
Evolocumab consistently lowers low-density lipoprotein cholesterol among diverse patient populations
Crossref
PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment.
Frontiers in Cardiovascular Medicine · 2026 · PubMed